Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Pieris Pharma (PIRS)

Pieris Pharma (PIRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 85,567
  • Shares Outstanding, K 74,406
  • Annual Sales, $ 31,420 K
  • Annual Income, $ -45,740 K
  • 60-Month Beta 1.06
  • Price/Sales 2.72
  • Price/Cash Flow N/A
  • Price/Book 1.92
Trade PIRS with:

Options Overview Details

View History
  • Implied Volatility 430.05% ( -38.88%)
  • Historical Volatility 51.07%
  • IV Percentile 94%
  • IV Rank 37.42%
  • IV High 1,050.86% on 08/25/22
  • IV Low 58.80% on 03/09/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 6
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 2,449
  • Open Int (30-Day) 2,645

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.16
  • Number of Estimates 2
  • High Estimate -0.13
  • Low Estimate -0.19
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1000 +4.55%
on 09/27/22
1.5500 -25.81%
on 09/12/22
-0.3200 (-21.77%)
since 08/30/22
3-Month
1.1000 +4.55%
on 09/27/22
2.1150 -45.63%
on 07/08/22
-0.7200 (-38.50%)
since 06/30/22
52-Week
1.1000 +4.55%
on 09/27/22
5.2950 -78.28%
on 10/01/21
-4.0200 (-77.76%)
since 09/30/21

Most Recent Stories

More News
Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue Estimates

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -27.27% and 64.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

PIRS : 1.1500 (unch)
IBRX : 4.97 (+0.61%)
Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference

BOSTON, MA / ACCESSWIRE / June 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...

PIRS : 1.1500 (unch)
Chau Khuong Joins Catalio Capital Management as General Partner

Catalio Capital Management, LP (“Catalio”), a leading multi-strategy life sciences investment firm, today announced that Chau Khuong, who was most recently a Partner at OrbiMed Advisors, has joined...

FUSN : 3.01 (+1.69%)
GKOS : 53.24 (-0.54%)
NTLA : 55.96 (+1.21%)
ICPT : 13.95 (-14.99%)
INSP : 177.37 (+0.14%)
NXTC : 2.75 (-2.14%)
PIRS : 1.1500 (unch)
Pieris Pharmaceuticals (PIRS) Loses 41.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Pieris Pharmaceuticals (PIRS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts...

PIRS : 1.1500 (unch)
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference

BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...

PIRS : 1.1500 (unch)
After Plunging 45.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pieris Pharmaceuticals (PIRS)

The heavy selling pressure might have exhausted for Pieris Pharmaceuticals (PIRS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street...

PIRS : 1.1500 (unch)
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 41.67% and 2.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

PIRS : 1.1500 (unch)
ARAV : 0.8172 (-7.65%)
Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDT BOSTON, MA / ACCESSWIRE / May 11, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology...

PIRS : 1.1500 (unch)
Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

PIRS : 1.1500 (unch)
3 Risky Stocks With Huge Potential Upside

Why risk-tolerant investors want to own Shopify, Silvergate Capital, and Pieris Pharmaceuticals.

PIRS : 1.1500 (unch)
SI : 75.35 (+1.15%)
SHOP : 26.94 (+0.64%)
AMZN : 113.00 (-1.57%)
NVAX : 18.20 (-1.99%)
AZN : 54.84 (-0.13%)
SGEN : 136.83 (+0.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.

See More

Key Turning Points

3rd Resistance Point 1.2700
2nd Resistance Point 1.2300
1st Resistance Point 1.1900
Last Price 1.1500
1st Support Level 1.1100
2nd Support Level 1.0700
3rd Support Level 1.0300

See More

52-Week High 5.2950
Fibonacci 61.8% 3.6925
Fibonacci 50% 3.1975
Fibonacci 38.2% 2.7025
Last Price 1.1500
52-Week Low 1.1000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar